LLY vs. AMGN, BIIB, INCY, MRNA, VKTX, VRTX, ABBV, JNJ, MRK, and PFE
Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), Moderna (MRNA), Viking Therapeutics (VKTX), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.
Eli Lilly and Company vs. Its Competitors
Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
In the previous week, Eli Lilly and Company had 94 more articles in the media than Amgen. MarketBeat recorded 198 mentions for Eli Lilly and Company and 104 mentions for Amgen. Amgen's average media sentiment score of 1.08 beat Eli Lilly and Company's score of 0.84 indicating that Amgen is being referred to more favorably in the media.
Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.
Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 1.0%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 48.8% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Eli Lilly and Company has a net margin of 22.67% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Eli Lilly and Company's return on equity.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Amgen currently has a consensus target price of $303.76, suggesting a potential upside of 5.39%. Eli Lilly and Company has a consensus target price of $990.89, suggesting a potential upside of 58.50%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Amgen.
Summary
Eli Lilly and Company beats Amgen on 13 of the 20 factors compared between the two stocks.
Get Eli Lilly and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Company Competitors List
Related Companies and Tools
This page (NYSE:LLY) was last updated on 8/8/2025 by MarketBeat.com Staff
